Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 4/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20596706 | 0.83 | SLC6A4 (0.35) | SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL20596703 | 0.83 | TACR1 (0.40) | KDM4ESLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL16408196 | 0.81 | KDM4E (0.40) | KDM4ESLC6A2SLC6A4CHRM1ALDH1A1 | |
| SCHEMBL22797936 | 0.81 | SLC6A4 (0.41) | SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL22449324 | 0.81 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL22797956 | 0.81 | TACR1 (0.39) | SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL26599372 | 0.80 | KDM4E (0.36) | KDM4EALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL3008298 | 0.80 | USP30 (0.38) | SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL22797790 | 0.80 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22797911 | 0.79 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | KDM4E 1410/4885SLC6A2 1937/4885SLC6A4 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.